DailyIQ
|
Sector:HealthcareAll sectors
Last updated 3 minutes ago

SYK·Stryker Corporation

$.
+. (+.%)
After Hours
High
$331.58
Open
$328.06
Market Cap
126.42B
52W High
$404.87
Low
$327.00
P. Close
$329.76
P/E
37.89
52W Low
$281.00
Fwd P/E
19.72
DailyIQ Est.
$400.42
Technical Score (1D)
82
BUY
News Sentiment
53
MIXED
BMO Capital’s 4‑hour‑old coverage of Stryker, issuing an outperform rating, signals a bullish view that could lift investor sentiment and valuation over the next week. The analyst’s forecast of growth in Stryker’s medical‑device business underpins this optimism, suggesting the company may continue to outperform peers in the near term. However, the 10‑hour‑old removal from several Russell growth indices could reduce passive exposure, potentially dampening demand from index‑tracking funds. Compounding this, a cyberattack that disrupted operations last week raises concerns about operational resilience and could weigh on short‑term trading volumes. Active investors’ renewed interest, noted in the same report, may offset some passive sell pressure, but the net effect remains uncertain. The upcoming Q2 earnings release, scheduled for later this month, is expected to confirm double‑digit earnings growth, which would validate the recent bullish narrative and influence guidance for the rest of the year. Bell Global Equities Fund’s addition of Stryker to its May 2026 portfolio, announced 13 hours ago, signals institutional confidence that could attract further buying pressure amid a broader equity rally. Traders should watch how the earnings report aligns with the analyst forecast and whether the cyberattack’s impact is fully absorbed, as this will determine the stock’s trajectory in the next 1–10 trading days. Additionally, monitoring index rebalancing activity and any further coverage updates will help gauge passive versus active mandate shifts that could sway short‑term liquidity.
Earnings Summary
Stryker Corporation (SYK) is a global medical technology company that designs and manufactures surgical equipment, neurotechnology devices, and orthopedic implants, serving hospitals and healthcare providers in roughly 75 countries. Operating within the healthcare sector, its MedSurg and Neurotechnology and Orthopaedics segments drive revenue through a diversified product portfolio that supports minimally invasive procedures and joint replacement surgeries. In the most recent reporting cycle, Stryker delivered Q1 2026 earnings of $2.60 per share against a $2.98 estimate, a decline from the $4.47 per share reported in Q4 2025, while revenue fell from $7.17 billion to $6.02 billion, marking a notable deceleration relative to the prior quarter’s growth. Across the last six quarters, the company has consistently outperformed analyst expectations, with five of six earnings reports beating estimates and only the most recent quarter missing on EPS; revenue, however, has slipped below guidance in both Q4 2025 and Q1 2026, indicating a tightening margin environment. Historically, Stryker has maintained a trajectory of rising earnings and revenue, with incremental gains each quarter until the recent dip, and has shown resilience in beating EPS forecasts even when revenue estimates are not met. Recent coverage highlights a cyberattack that disrupted operations, the removal from several Russell growth indices, and a bullish analyst outlook that could influence short‑term sentiment; the launch of the TPX HD power tool and institutional additions to its portfolio suggest continued product pipeline momentum. Investors should watch the upcoming Q2 2026 earnings release for guidance on revenue and margin expectations, assess how the company absorbs the cyberattack’s operational impact, and monitor index rebalancing activity that may affect passive inflows, as these factors will shape the next quarter’s performance.

EPS

EstBeatMiss
$2.32$2.93$3.54$4.14$4.75Q1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$3.49 - -
Q1'26$2.98$2.60-12.9%
Q4'25$4.44$4.47+0.7%
Q3'25$3.13$3.19+1.9%
Q2'25$3.07$3.13+1.9%
Q1'25$2.73$2.84+4.0%

Revenue

EstBeatMiss
$5.7B$6.1B$6.5B$7.0B$7.4BQ1'25Q2'25Q3'25Q4'25Q1'26Q2'26
QtrEstActual+/−
Q2'26$6.6B - -
Q1'26$6.3B$6.0B-4.9%
Q4'25$7.2B$7.2B-0.3%
Q3'25 - $6.1B -
Q2'25 - $6.0B -
Q1'25 - $5.9B -
Full Earnings BreakdownEstimates, actuals, guidance, and historical context
→

Market Data

SYK Stock Snapshot

SYK is currently trading at $329.28, giving Stryker Corporation a market cap of 126.42B and a P/E ratio of 37.9. Today's range spans $327.00–$331.58, with shares opening at $328.06 and moving down $0.48 (0.1%) from the prior close. DailyIQ's technical score sits at 82/100 (BUY) with a news sentiment reading of 53/100.

Over the past year SYK has traded between $281.00 and $404.87 - the current price is +17.2% off the 52-week low and -18.7% from the high. 37 analysts cover the stock with a Buy consensus and a mean 12-month target of $385.92 (range $315.00–$465.00), implying upside of +17.2%.

In the Healthcare peer group, Stryker Corporation (SYK) stands out for a BUY signal backed by aligned sentiment - score 82/100, sentiment neutral at 53/100, price $329.28 (in the lower half of its 52-week range). (P/E: 37.9) With 126.42B in market cap, this is large enough to feature on institutional watch lists but small enough to re-rate meaningfully on a positive earnings surprise. The 52-week span of $281.00–$404.87 shows the stock has already proven it can make significant moves.

What makes SYK's BUY setup (82/100) particularly actionable at 126.42B in Healthcare capitalization is the scale-to-move ratio: large enough to feature on institutional mandates but not so large that the percentage upside is already compressed by index inertia. At $329.28 (in the lower half of its 52-week range in $281.00–$404.87), with sentiment running neutral at 53/100, the setup rewards conviction-sized positioning more than it does speculative small bets.